论文信息 - First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. - 字舞流文

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.

R. Advani | J. Bendell | P. Munster | T. Yap | T. O'Shea | J. Englert | G. Falchook | R. Lynch | M. Gutierrez | S. Doleman | M. Renschler | M. Hamadani | Monika L. Burness | N. Palmisiano | M. Patel | W. D. Bradley